Quick Answer
Seres Therapeutics, Inc. reported Total Revenue of $789.0 thousand for fiscal year 2025.
Seres Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $789.0K | — |
| 2024 | $0.00 | — |
| 2023 | $0.00 | -100.0% |
| 2022 | $7.13M | -95.1% |
| 2021 | $144.93M | +336.3% |
| 2020 | $33.22M | -3.7% |
| 2019 | $34.51M | +22.1% |
| 2018 | $28.27M | -11.9% |
| 2017 | $32.10M | +47.5% |
| 2016 | $21.77M | — |
| 2015 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $351.0K | — | — |
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | +100.0% | -100.0% |
| September 30, 2023 | $310.0K | -91.0% | -99.8% |
| June 30, 2023 | $126.47M | +10300.7% | +24328.5% |
| March 31, 2023 | -$522.0K | -135.0% | -115.2% |
| September 30, 2022 | $3.44M | -97.3% | +183.2% |
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: